Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT02757105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02757105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2016
Completion date
July 14, 2017
Enrollment
127 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea